Moberg Derma receives EU/EEA CE mark approval for Kaprolac Skin Repair & Hydration

Moberg Derma AB (publ.) (STO:MOB) announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA.

Kaprolac Skin Repair & Hydration is a new, steroid-free treatment option for eczema and dry skin, such as atopic eczema. Treatment of eczema is a field which has been dominated by older products, with few new launches over the past few years, and Kaprolac Skin Repair & Hydration has properties which meet significant needs in the treatment of atopic eczema.

"We are now looking forward to working together with partners and distributors to make this product available to patients. The benign safety profile makes this Kaprolac product an interesting alternative for patients who are affected by recurrent and protracted problems with eczema. In a comparative study, the product demonstrated a greater ability to reinforce the skin barrier and re-hydrate the skin than a topical pharmaceutical based on propylene glycol," comments Peter Wolpert, CEO of Moberg Derma.